Drug Trial Radar · NCT06129409
Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Oct 10, 2023
Primary completion
Apr 15, 2024
Study completion Apr 15, 2024
Sponsor
- Lead sponsor
- NodThera Ltd. (a Rezera company)Industry
- Sponsor type
- Industry
- First posted
- Nov 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled Study to Assess the Effect of NT-0796 on Inflammation in Obese Participants at Risk of Cardiovascular Disease. Participants will be admitted to an in-patient Clinical Research Unit on Day -1 and will be discharged on Day 30. The trial will include a 7-day out-patient safety follow-up period following the last dose of study treatment. For the first approximately 20 participants effect of food will be evaluated on the Pharmacokinetics of NT-0796. MRI's will be conducted in a subset of participants.
Conditions
- Cardiovascular Diseases
Interventions
NT-0796Drug
Orally administered capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in hsCRP levelsTime frame: Baseline to Day 28
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Investigative Site
Miami, Florida
Investigative Site
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.